These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 34482532)

  • 1. Intravitreal Dexamethasone Implant in Patients Who Did Not Complete Anti-VEGF Loading Dose During the COVID-19 Pandemic: a Retrospective Observational Study.
    Scorcia V; Giannaccare G; Gatti V; Vaccaro S; Piccoli G; Villì A; Toro MD; Yu AC; Iovino C; Simonelli F; Carnevali A
    Ophthalmol Ther; 2021 Dec; 10(4):1015-1024. PubMed ID: 34482532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema.
    Busch C; Zur D; Fraser-Bell S; Laíns I; Santos AR; Lupidi M; Cagini C; Gabrielle PH; Couturier A; Mané-Tauty V; Giancipoli E; Ricci GD; Cebeci Z; Rodríguez-Valdés PJ; Chaikitmongkol V; Amphornphruet A; Hindi I; Agrawal K; Chhablani J; Loewenstein A; Iglicki M; Rehak M;
    Acta Diabetol; 2018 Aug; 55(8):789-796. PubMed ID: 29730822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexamethasone intravitreal implant in diabetic macular oedema refractory to anti-vascular endothelial growth factors: the AUSSIEDEX study.
    Mitchell P; Arnold J; Fraser-Bell S; Kang HK; Chang AA; Tainton J; Simonyi S
    BMJ Open Ophthalmol; 2023 Aug; 8(1):. PubMed ID: 37541745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
    Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT.
    Ozsaygili C; Duru N
    Retina; 2020 Jun; 40(6):1044-1052. PubMed ID: 30950970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results.
    Busch C; Fraser-Bell S; Iglicki M; Lupidi M; Couturier A; Chaikitmongkol V; Giancipoli E; Rodríguez-Valdés PJ; Gabrielle PH; Laíns I; Santos AR; Cebeci Z; Amphornphruet A; Degenhardt V; Unterlauft JD; Cagini C; Mané-Tauty V; D'Amico Ricci G; Hindi I; Agrawal K; Chhablani J; Loewenstein A; Zur D; Rehak M;
    Acta Diabetol; 2019 Dec; 56(12):1341-1350. PubMed ID: 31541334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-Month Outcomes of Intravitreal Anti-VEGF vs. Dexamethasone Implant in the Treatment of Diabetic Macular Edema in Vitrectomized Eyes.
    Liang Y; Yan B; Xie M; Meng Z; Ma J; Ma B; Luo J
    Front Med (Lausanne); 2022; 9():895220. PubMed ID: 35774995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study.
    Augustin AJ; Kuppermann BD; Lanzetta P; Loewenstein A; Li XY; Cui H; Hashad Y; Whitcup SM;
    BMC Ophthalmol; 2015 Oct; 15():150. PubMed ID: 26519345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective, Observational, Multicenter, Real-World Study of the Efficacy, Safety, and Pattern of Use of the Dexamethasone Intravitreal Implant in Diabetic Macular Edema in France: Short-Term Outcomes of LOUVRE 3.
    Kodjikian L; Delcourt C; Creuzot-Garcher C; Massin P; Conrath J; Velard MÈ; Lassalle T; Pinchinat S; Dupont-Benjamin L
    Ophthalmol Ther; 2023 Jun; 12(3):1671-1692. PubMed ID: 36967448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal dexamethasone implant in naïve and previously treated patients with diabetic macular edema: a retrospective study.
    Medina-Baena M; Cejudo-Corbalán O; García-Pulido JI; Huertos-Carrillo MJ; Girela-López E
    Int J Ophthalmol; 2020; 13(10):1597-1605. PubMed ID: 33078111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of dexamethasone intravitreal implant in patients with retinal vein occlusion resistant to anti-VEGF therapy: a 12-month prospective study.
    Georgalas L; Tservakis I; Kiskira EE; Petrou P; Papaconstantinou D; Kanakis M
    Cutan Ocul Toxicol; 2019 Dec; 38(4):330-337. PubMed ID: 31060385
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience.
    Blanc J; Deschasse C; Kodjikian L; Dot C; Bron AM; Creuzot-Garcher C
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1441-1448. PubMed ID: 29855706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Dexamethasone Intravitreal Implant in Naïve and Previously Treated Patients with Diabetic Macular Edema.
    Medina-Baena M; Cejudo-Corbalán O; Labella-Quesada F; Girela-López E
    Int J Environ Res Public Health; 2023 Apr; 20(8):. PubMed ID: 37107744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiation of intravitreal aflibercept injection treatment in patients with diabetic macular edema: a review of VIVID-DME and VISTA-DME data.
    Ziemssen F; Schlottman PG; Lim JI; Agostini H; Lang GE; Bandello F
    Int J Retina Vitreous; 2016; 2():16. PubMed ID: 27847634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France.
    Korobelnik JF; Kodjikian L; Delcourt C; Gualino V; Leaback R; Pinchinat S; Velard ME
    Graefes Arch Clin Exp Ophthalmol; 2016 Dec; 254(12):2307-2318. PubMed ID: 27286894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Intravitreal Fluocinolone Acetonide Implant for Chronic Diabetic Macular Edema Previously Treated in Real-Life Practice: The REALFAc Study.
    Mathis T; Papegaey M; Ricard C; Rezkallah A; Matonti F; Sudhalkar A; Vartin C; Dot C; Kodjikian L
    Pharmaceutics; 2022 Mar; 14(4):. PubMed ID: 35456557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Different Clinical Baseline Characteristics on Intravitreal Dexamethasone Implant Ozurdex
    Udaondo P; Hervas-Ontiveros A; Rosemblatt A; Garcia-Delpech S
    Clin Ophthalmol; 2021; 15():4153-4162. PubMed ID: 34703201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal Dexamethasone Implant in Anti-Vascular Endothelial Growth Factor Pretreated Diabetic Macular Edema-A Swiss Cohort Study.
    Turgut F; Somfai GM; Tappeiner C; Hatz K; Mantel I; Ambresin A; Donati G; Guignard V; Nagyová D; Pfister IB; Schild C; Garweg JG
    Pharmaceuticals (Basel); 2024 Sep; 17(9):. PubMed ID: 39338397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexamethasone implant for refractory macular edema secondary to diabetic retinopathy and retinal vein occlusion.
    Zhong YY; Tang C; Zhang LY; Zhang XD; Liu SL
    Int J Ophthalmol; 2024; 17(10):1837-1842. PubMed ID: 39430031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Early efficacy of dexamethasone implant (OZURDEX
    Sarda V; Fajnkuchen F; Nghiem-Buffet S; Grenet T; Chaine G; Giocanti-Auregan A
    J Fr Ophtalmol; 2017 May; 40(5):408-413. PubMed ID: 28336283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.